Persistent interferon-ß-1b-induced psychosis in a patient with multiple sclerosis.
作者： Giovanni Manfredi , Giorgio D. Kotzalidis , Gabriele Sani , Alexia E. Koukopoulos , Valeria Savoja
DOI: 10.1111/J.1440-1819.2010.02122.X
关键词:
摘要: Interferon-s is used in patients with multiple sclerosis to reduce autoimmunity; although other psychiatric side-effects are common, contrast interferon-alpha, psychosis has been reported only once. A patient developed auditory hallucinations, paranoid delusions, and increased aggressiveness after 16 months of treatment interferon-s-1b, 250 mg every day. He responded about one month antipsychotic treatment, but tended relapse upon dose reduction, 2 years still needs antipsychotics control his symptoms. Because there was no change magnetic resonance imaging between pre- post-treatment interferon, we concluded that more related interferon than the underlying disease.
sci-hub.se 参考文章(18)
W. Gaebel, J. Kornischka, W. Burtscheidt, Interferoninduzierte paranoide PsychoseLiteraturübersicht und Kasuistik Nervenarzt. ,vol. 73, pp. 463- 467 ,(2002) , 10.1007/S00115-001-1224-9
Martin Dresler, Lisa Genzel, Michael Kluge, Petra Schüssler, Frank Weber, Marcus Rosenhagen, Axel Steiger, Off-line memory consolidation impairments in multiple sclerosis patients receiving high-dose corticosteroid treatment mirror consolidation impairments in depression Psychoneuroendocrinology. ,vol. 35, pp. 1194- 1202 ,(2010) , 10.1016/J.PSYNEUEN.2010.02.005
Vera Morgan, Aleksandar Janca, Assen Jablensky, Psychotic disorders in Australia: patients respond to national survey results. European Psychiatry. ,vol. 18, pp. 142- 142 ,(2003) , 10.1016/S0924-9338(03)00030-0
J.-L. Goeb, C. Even, G. Nicolas, B. Gohier, F. Dubas, J.B. Garré, Psychiatric side effects of interferon-β in multiple sclerosis European Psychiatry. ,vol. 21, pp. 186- 193 ,(2006) , 10.1016/J.EURPSY.2005.09.013
J. L. Goëb, A. Cailleau, P. Lainé, F. Etcharry-Bouyx, D. Maugin, Ph. Duverger, B. Gohier, K. Rannou-Dubas, F. Dubas, J. B. Garré, Acute Delirium, Delusion, and Depression During IFN-β-1a Therapy for Multiple Sclerosis: A Case Report Clinical Neuropharmacology. ,vol. 26, pp. 5- 7 ,(2003) , 10.1097/00002826-200301000-00002
J. Thome, U. Knopf, Acute psychosis after injection of pegylated interferon alpha-2a. European Psychiatry. ,vol. 18, pp. 143- ,(2003) , 10.1016/S0924-9338(03)00032-4
David Telio, Sanjeev Sockalingam, Vicky Stergiopoulos, Persistent psychosis after treatment with interferon alpha: a case report. Journal of Clinical Psychopharmacology. ,vol. 26, pp. 446- 447 ,(2006) , 10.1097/01.JCP.0000227348.59912.5D
C A Naranjo, U Busto, E M Sellers, P Sandor, I Ruiz, E A Roberts, E Janecek, C Domecq, D J Greenblatt, A method for estimating the probability of adverse drug reactions Clinical Pharmacology and Therapeutics. ,vol. 30, pp. 239- 245 ,(1981) , 10.1038/CLPT.1981.154
S. B. Patten, C. A. Beck, J. V.A. Williams, C. Barbui, L. M. Metz, Major depression in multiple sclerosis A population-based perspective Neurology. ,vol. 61, pp. 1524- 1527 ,(2003) , 10.1212/01.WNL.0000095964.34294.B4
Jeffrey P. Reiss, Diana Sam, Jitender Sareen, Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans. Journal of Clinical Neuroscience. ,vol. 13, pp. 282- 284 ,(2006) , 10.1016/J.JOCN.2005.02.017